ASP 0777
/ Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 30, 2024
A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Astellas Pharma Inc | Phase classification: P1b ➔ P1
Phase classification • Alzheimer's Disease • CNS Disorders
January 22, 2013
Safety and tolerability of the NMDA-receptor antagonist ASP0777 in patients with Alzheimer's disease on stable doses of donepezil
(ADPD 2013)
- Presentation time: 05.03.2013, 08:00-13:00; P1, N=60; NCT01406145; "Baseline MMSE scores ranged from 18−26...In this population...ASP0777 ≤20 mg daily for 6 weeks resulted in no safety or tolerability issues. Plasma concentrations of ASP0777 were dose dependent."
P1 data • Alzheimer's Disease
1 to 2
Of
2
Go to page
1